Emma Colvill
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emma Colvill has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Paul Keall
The University of Sydney
15 shared publications - Per Rugaard Poulsen
Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark
11 shared publications - Andrew Kneebone
Department of Radiation Oncology Royal North Shore Hospital Sydney New South Wales Australia
8 shared publications - Ricky O’ Brien
ACRF Image X Institute, University of Sydney, Sydney, Australia
8 shared publications - Thomas Eade
Northern Sydney Clinical School, Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
8 shared publications - Jeremy Todd Booth
Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards
6 shared publications
Latest Publications
- 1 May 2019
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 134, 135-142
The dosimetric effect of residual breath-hold motion in pencil beam scanned proton therapy – An experimental study
- 1 May 2019
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 134, 135-142
The dosimetric effect of residual breath-hold motion in pencil beam scanned proton therapy – An experimental study
- 1 June 2018
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 101 (2) , 387-395
Electromagnetic-Guided MLC Tracking Radiation Therapy for Prostate Cancer Patients: Prospective Clinical Trial Results
- 1 June 2018
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 101 (2) , 387-395
Electromagnetic-Guided MLC Tracking Radiation Therapy for Prostate Cancer Patients: Prospective Clinical Trial Results
- 17 July 2017
- Published by Springer Nature in Australasian Physics & Engineering Sciences in Medicine
- Vol. 40 (3) , 643-649
Performance assessment of a programmable five degrees-of-freedom motion platform for quality assurance of motion management techniques in radiotherapy
Inter-fraction and intra-fraction motion management methods are increasingly applied clinically and require the development of advanced motion platforms to facilitate testing and quality assurance program development. The aim of this study was to assess the performance of a 5 degrees-of-freedom (DoF) programmable motion platform HexaMotion (ScandiDos, Uppsala, Sweden) towards clinically observed tumor motion range, velocity, acceleration and the accuracy requirements of SABR prescribed in AAPM Task Group 142. Performance specifications for the motion platform were derived from literature regarding the motion characteristics of prostate and lung tumor targets required for real time motion management. The performance of the programmable motion platform was evaluated against (1) maximum range, velocity and acceleration (5 DoF), (2) static position accuracy (5 DoF) and (3) dynamic position accuracy using patient-derived prostate and lung tumor motion traces (3 DoF). Translational motion accuracy was compared against electromagnetic transponder measurements. Rotation was benchmarked with a digital inclinometer. The static accuracy and reproducibility for translation and rotation was <0.1 mm or <0.1°, respectively. The accuracy of reproducing dynamic patient motion was <0.3 mm. The motion platform’s range met the need to reproduce clinically relevant translation and rotation ranges and its accuracy met the TG 142 requirements for SABR. The range, velocity and acceleration of the motion platform are sufficient to reproduce lung and prostate tumor motion for motion management. Programmable motion platforms are valuable tools in the investigation, quality assurance and commissioning of motion management systems in radiation oncology.
- 17 July 2017
- Published by Springer Nature in Australasian Physics & Engineering Sciences in Medicine
- Vol. 40 (3) , 643-649
Performance assessment of a programmable five degrees-of-freedom motion platform for quality assurance of motion management techniques in radiotherapy
Inter-fraction and intra-fraction motion management methods are increasingly applied clinically and require the development of advanced motion platforms to facilitate testing and quality assurance program development. The aim of this study was to assess the performance of a 5 degrees-of-freedom (DoF) programmable motion platform HexaMotion (ScandiDos, Uppsala, Sweden) towards clinically observed tumor motion range, velocity, acceleration and the accuracy requirements of SABR prescribed in AAPM Task Group 142. Performance specifications for the motion platform were derived from literature regarding the motion characteristics of prostate and lung tumor targets required for real time motion management. The performance of the programmable motion platform was evaluated against (1) maximum range, velocity and acceleration (5 DoF), (2) static position accuracy (5 DoF) and (3) dynamic position accuracy using patient-derived prostate and lung tumor motion traces (3 DoF). Translational motion accuracy was compared against electromagnetic transponder measurements. Rotation was benchmarked with a digital inclinometer. The static accuracy and reproducibility for translation and rotation was <0.1 mm or <0.1°, respectively. The accuracy of reproducing dynamic patient motion was <0.3 mm. The motion platform’s range met the need to reproduce clinically relevant translation and rotation ranges and its accuracy met the TG 142 requirements for SABR. The range, velocity and acceleration of the motion platform are sufficient to reproduce lung and prostate tumor motion for motion management. Programmable motion platforms are valuable tools in the investigation, quality assurance and commissioning of motion management systems in radiation oncology.
- 1 July 2017
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 124 (1) , 18-24
MLC tracking for lung SABR reduces planning target volumes and dose to organs at risk
- 1 July 2017
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 124 (1) , 18-24
MLC tracking for lung SABR reduces planning target volumes and dose to organs at risk
- 27 February 2017
- Published by Springer Nature in Australasian Physics & Engineering Sciences in Medicine
- Vol. 40 (2) , 317-324
Quantification of intrafraction prostate motion and its dosimetric effect on VMAT
Intrafraction prostate motion degrades the accuracy of radiation therapy (RT) delivery. Whilst a number of metrics in the literature have been used to quantify intrafraction prostate motion, it has not been established whether these metrics reflect the effect of motion on the RT dose delivered to the patients. In this study, prostate motion during volumetric modulated arc therapy (VMAT) treatment of 18 patients and a total of 294 fractions was quantified through novel metrics as well as those available in the literature. The impact of the motion on VMAT dosimetry was evaluated using these metrics and dose reconstructions based on a previously validated and published method. The dosimetric impact of the motion on planning target volume (PTV) and clinical target volume (CTV) coverage and organs at risk (OARs) was correlated with the motion metrics, using the coefficient of determination (R2), to evaluate their utility. Action level threshold for the prostate motion metric that best described the dosimetric impact on the PTV D95% was investigated through iterative regression analysis. The average (range) of the mean motion for the patient cohort was 1.5 mm (0.3–9.9 mm). A number of motion metrics were found to be strongly correlated with PTV D95%, the range of R2 was 0.43–0.81. For all the motion measures, correlations with CTV D99% (range of R2 was 0.12–0.62), rectum V65% (range of R2 was 0.33–0.58) and bladder V65% (range of R2 was 0.51–0.69) were not as strong as for PTV D95%. The mean of the highest 50% of motion metric was one of the best indicator of dosimetric impact on PTV D95%. Action level threshold value for this metric was found to be 3.0 mm. For an individual fraction, when the metric value was greater than 3.0 mm then the PTV D95% was reduced on average by 6.2%. This study demonstrated that several motion metrics are well correlated with the dosimetric impact (PTV D95%) of individual fraction prostate motion on VMAT delivery and could be used for treatment course adaptation.
- 27 February 2017
- Published by Springer Nature in Australasian Physics & Engineering Sciences in Medicine
- Vol. 40 (2) , 317-324
Quantification of intrafraction prostate motion and its dosimetric effect on VMAT
Intrafraction prostate motion degrades the accuracy of radiation therapy (RT) delivery. Whilst a number of metrics in the literature have been used to quantify intrafraction prostate motion, it has not been established whether these metrics reflect the effect of motion on the RT dose delivered to the patients. In this study, prostate motion during volumetric modulated arc therapy (VMAT) treatment of 18 patients and a total of 294 fractions was quantified through novel metrics as well as those available in the literature. The impact of the motion on VMAT dosimetry was evaluated using these metrics and dose reconstructions based on a previously validated and published method. The dosimetric impact of the motion on planning target volume (PTV) and clinical target volume (CTV) coverage and organs at risk (OARs) was correlated with the motion metrics, using the coefficient of determination (R2), to evaluate their utility. Action level threshold for the prostate motion metric that best described the dosimetric impact on the PTV D95% was investigated through iterative regression analysis. The average (range) of the mean motion for the patient cohort was 1.5 mm (0.3–9.9 mm). A number of motion metrics were found to be strongly correlated with PTV D95%, the range of R2 was 0.43–0.81. For all the motion measures, correlations with CTV D99% (range of R2 was 0.12–0.62), rectum V65% (range of R2 was 0.33–0.58) and bladder V65% (range of R2 was 0.51–0.69) were not as strong as for PTV D95%. The mean of the highest 50% of motion metric was one of the best indicator of dosimetric impact on PTV D95%. Action level threshold value for this metric was found to be 3.0 mm. For an individual fraction, when the metric value was greater than 3.0 mm then the PTV D95% was reduced on average by 6.2%. This study demonstrated that several motion metrics are well correlated with the dosimetric impact (PTV D95%) of individual fraction prostate motion on VMAT delivery and could be used for treatment course adaptation.
- 7 June 2016
- Published by Wiley in Medical Physics
- Vol. 43 (6Part26) , 3650
SU-G-JeP1-12: Head-To-Head Performance Characterization of Two Multileaf Collimator Tracking Algorithms for Radiotherapy
- 7 June 2016
- Published by Wiley in Medical Physics
- Vol. 43 (6Part26) , 3650
SU-G-JeP1-12: Head-To-Head Performance Characterization of Two Multileaf Collimator Tracking Algorithms for Radiotherapy
- Open Access
- 1 April 2016
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 119 (1) , 159-165
A dosimetric comparison of real-time adaptive and non-adaptive radiotherapy: A multi-institutional study encompassing robotic, gimbaled, multileaf collimator and couch tracking
- 1 April 2016
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 119 (1) , 159-165
Open AccessA dosimetric comparison of real-time adaptive and non-adaptive radiotherapy: A multi-institutional study encompassing robotic, gimbaled, multileaf collimator and couch tracking
- 1 April 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 94 (5) , 1015-1021
Real-Time 3D Image Guidance Using a Standard LINAC: Measured Motion, Accuracy, and Precision of the First Prospective Clinical Trial of Kilovoltage Intrafraction Monitoring–Guided Gating for Prostate Cancer Radiation Therapy
- 1 April 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 94 (5) , 1015-1021
Real-Time 3D Image Guidance Using a Standard LINAC: Measured Motion, Accuracy, and Precision of the First Prospective Clinical Trial of Kilovoltage Intrafraction Monitoring–Guided Gating for Prostate Cancer Radiation Therapy
- Open Access
- 1 November 2015
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 93 (3) , S192-S193
Sub-mm Accuracy Results Measured From the First Prospective Clinical Trial of a Novel Real-Time IGRT System, Kilovoltage Intrafraction Monitoring (KIM)
- 1 November 2015
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 93 (3) , S192-S193
Open AccessSub-mm Accuracy Results Measured From the First Prospective Clinical Trial of a Novel Real-Time IGRT System, Kilovoltage Intrafraction Monitoring (KIM)
- Open Access
- 24 October 2015
- Published by Springer Nature in Radiation Oncology
- Vol. 10 (1) , 215
Prostate motion during radiotherapy of prostate cancer patients with and without application of a hydrogel spacer: a comparative study
The use of a tissue expander (hydrogel) for sparing of the rectum from increased irradiation during prostate radiotherapy is becoming popular. The goal of this study is to investigate the effect of a tissue expander (hydrogel) on the intrafraction prostate motion during radiotherapy. Real time prostate motion was analysed for 26 patients and 742 fractions; 12 patients with and 14 patients without hydrogel (SpaceOAR™). The intra-fraction motion was quantified and compared between the two groups. The average (±standard deviation) of the mean motion during the treatment for patients with and without hydrogel was 1.5 (±0.8 mm) and 1.1 (±0.9 mm) respectively (p < 0.05). The average time of motion >3 mm for patients with and without hydrogel was 7.7 % (±1.1 %) and 4.5 % (±0.9 %) respectively (p > 0.05). The hydrogel age, fraction number and treatment time were found to have no effect (R 2 < 0.05) on the prostate motion. Differences in intrafraction motion in patients with hydrogel and without hydrogel were within measurement uncertainty (<1 mm). This result confirms that the addition of a spacer does not negate the need for intrafraction motion management if clinically indicated.
- 24 October 2015
- Published by Springer Nature in Radiation Oncology
- Vol. 10 (1) , 215
Open AccessProstate motion during radiotherapy of prostate cancer patients with and without application of a hydrogel spacer: a comparative study
The use of a tissue expander (hydrogel) for sparing of the rectum from increased irradiation during prostate radiotherapy is becoming popular. The goal of this study is to investigate the effect of a tissue expander (hydrogel) on the intrafraction prostate motion during radiotherapy. Real time prostate motion was analysed for 26 patients and 742 fractions; 12 patients with and 14 patients without hydrogel (SpaceOAR™). The intra-fraction motion was quantified and compared between the two groups. The average (±standard deviation) of the mean motion during the treatment for patients with and without hydrogel was 1.5 (±0.8 mm) and 1.1 (±0.9 mm) respectively (p < 0.05). The average time of motion >3 mm for patients with and without hydrogel was 7.7 % (±1.1 %) and 4.5 % (±0.9 %) respectively (p > 0.05). The hydrogel age, fraction number and treatment time were found to have no effect (R 2 < 0.05) on the prostate motion. Differences in intrafraction motion in patients with hydrogel and without hydrogel were within measurement uncertainty (<1 mm). This result confirms that the addition of a spacer does not negate the need for intrafraction motion management if clinically indicated.